Agenus

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agenus reports robust Q4 earnings, advances immuno-oncology pipeline

Agenus showcased strong financials, progress in immuno-oncology pipeline, and durable responses in various cancers
Strategic partnerships and innovative R&D capabilities position the company well for future growth and development
Challenges in enrollment, differentiation, and managing immune-related toxicities are being actively addressed for continued success

Agenus (AGEN) reports progress in cancer treatment programs

Agenus (AGEN) showcased strong progress in its cancer treatment programs, with notable response rates and Fast Track Designation for a promising combination therapy.
While financials remained stable, the company faces challenges in maintaining response rates and successful study enrollments, requiring effective regulatory navigation and communication strategies.
Opportunities for Agenus include presenting at ASCO, expanding development programs, and attracting partnerships to drive further advancements in oncology treatments.

Agenus reports positive trial outcomes and strong regulatory strategy

Agenus is making significant progress in cancer treatment with positive trial outcomes and a strong regulatory strategy.
The company's commitment to innovation, patient quality of life, and managing side effects positions them well for future success.
Challenges include addressing analyst inquiries, enrollment in studies, and managing toxicities, but opportunities exist in partnerships and targeted treatment approaches.

Agenus reports robust earnings, eyes strategic partnerships for growth

Agenus Inc. demonstrated strong financial performance and progress in its BOT/BAL program.
While facing challenges in trial enrollment and funding, the company is focused on strategic partnerships.
Opportunities lie in upcoming data disclosures, potential BLA submissions, and product launches.

Agenus reports Q1 2024 financials, progresses BOT/BAL program for growth

Agenus navigates financial challenges with a focus on advancing the BOT/BAL program towards commercialization. Despite losses, the company's strategic initiatives position it for potential growth opportunities through milestone achievements and market expansion.

Agenus (AGEN) reports Q3 loss, advances cancer therapy innovations

Agenus (AGEN) is navigating financial challenges with a focus on advancing transformative cancer therapy and strategic partnerships.
Despite a net loss of $67 million, progress in BOT/BAL development and strategic initiatives position Agenus for future growth.
Opportunities in upcoming clinical studies and data readouts in 2025 underscore the company's commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Welcomes Investors Of Agenus Inc To Join The Securities Fraud Probe

LOS ANGELES, CA / ACCESSWIRE / August 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Agenus Inc Are Invited To Participate In The Securities Fraud Investigation Conducted By The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Agenus Inc Can Join The Securities Fraud Investigation Conducted By The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Agenus Inc Are Encouraged To Participate In The Securities Fraud Investigation Led By The Schall Law Firm

Agenus, Inc. (NASDAQ:AGEN ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Zack Armen - Head, IR Garo Armen - Chairman & CEO Steven O'Day - CMO Christine Klaskin - VP, Finance Robin Taylor - CCO Tom Harrison - Board of Directors Conference Call Participants Emily Bodnar - H.C. Wainright Claire Duffy - Jefferies Madison El-Saadi - B.

Agenus, Inc. (AGEN) Q2 2024 Earnings Call Transcript

Agenus (AGEN) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $4 per share a year ago.

Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the second quarter of 2024. “Agenus milestones this quarter include the release of interim data from our global randomized Phase 2 trial of BOT/BAL in relapsed/refractory MSS colorectal cancer, consistent with our Phase 1 results,” said Garo Armen, PhD, Chairman a.

Agenus Reports Second Quarter 2024 Operational and Financial Results

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's.

Agenus Announces Appointment of Tom Harrison to Board of Directors

LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Agenus Inc Are Invited To Join The Securities Fraud Investigation Led By The Schall Law Firm

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the publication of a seminal study in the prestigious Cancer Discovery, a journal of the American Association for Cancer Research, detailing the novel mechanism of action and effectiveness of botensilimab, an investigational, novel multifunctional anti-CTLA-4 antibody, in various treatment-resistant cancers. The paper, entitled “Botensilimab,.

Agenus Publishes Seminal Study on Botensilimab's Activity in Treatment-Resistant Cancers

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Agenus Inc Can Participate In The Securities Fraud Investigation Conducted By The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Clients to Contact the Firm!

Agenus (AGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Shareholders to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Shareholders to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Investors to Contact the Firm Today!

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

Investors who lost money on Agenus Inc. should contact Levi & Korsinsky about an ongoing investigation - AGEN

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Of Agenus Inc Can Participate In The Securities Fraud Investigation By The Schall Law Firm

Southwest Airlines

CommScope Hld

Green Thumb Industries Inc.

Hawaiian Electric Industries

MidCap Financial Investment Corp

Sabre

Summit Midstream Partners LP

Yandex

Serve Robotics Inc

We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Despite the decline in stock price for small biotech Agenus, one analyst thinks it could have further to go. Lithium Americas Corp. could be positioned for significant profitability with potential for 100-700% upside in share price.

Undercovered Dozen: Hawaiian Electrics, Serve Robotics, Yandex, Southwest Airlines +

AGEN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Agenus Inc. investment

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN). Investors who purchased Agenus securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AGEN.

AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Agenus Inc. and Encourages Stockholders to Contact the Firm!

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Confe.

Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agenus Inc. ("Agenus") (NASDAQ:AGEN) concerning possible violations of federal securities laws. Agenus issued a press release on July 18, 2024, "announc[ing] the results of its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the advancement of its immunotherapy combination, botensilimab (BOT) and balstilimab (BAL), for the treatment of adult patients with relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM).

News for Agenus Stock (AGEN)